These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 38697874)
1. Pathologic and survival outcomes following radical cystectomy for "progressive" and "de novo" muscle-invasive bladder cancer: A meta-analysis stratified by neoadjuvant chemotherapy status. Xia L; Dadabhoy A; Wood EL; Mehta SV; Roberson DS; Guzzo TJ; Bivalacqua TJ; Daneshmand S Urol Oncol; 2024 Oct; 42(10):333.e1-333.e13. PubMed ID: 38697874 [TBL] [Abstract][Full Text] [Related]
2. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841 [TBL] [Abstract][Full Text] [Related]
3. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837 [TBL] [Abstract][Full Text] [Related]
4. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. Seisen T; Jamzadeh A; Leow JJ; Rouprêt M; Cole AP; Lipsitz SR; Kibel AS; Nguyen PL; Sun M; Menon M; Bellmunt J; Choueiri TK; Trinh QD JAMA Oncol; 2018 Feb; 4(2):225-229. PubMed ID: 28837718 [TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients. Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762 [TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer. Li R; Nocera L; Rose KM; Raggi D; Naidu S; Mercinelli C; Cigliola A; Tateo V; Patanè D; Grass GD; Gilbert SM; Sexton WJ; Bandini M; Moschini M; Briganti A; Montorsi F; Spiess PE; Necchi A Eur Urol Oncol; 2024 Jun; 7(3):614-624. PubMed ID: 38184473 [TBL] [Abstract][Full Text] [Related]
8. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. Hensley PJ; Bree KK; Campbell MT; Alhalabi O; Kokorovic A; Miest T; Nogueras-Gonzalez GM; Gao J; Siefker-Radtke AO; Guo CC; Navai N; Dinney CP; Kamat AM J Urol; 2021 Nov; 206(5):1258-1267. PubMed ID: 34184926 [TBL] [Abstract][Full Text] [Related]
9. Pathological response and survival outcomes after neoadjuvant chemotherapy with radical cystectomy in octogenarians for muscle-invasive bladder cancer: an observational database study. Avudaiappan AP; Prabhakar P; Sandman MS; Rubens M; Garje R; Eldefrawy A; Manoharan M BMC Urol; 2024 Jul; 24(1):150. PubMed ID: 39049001 [TBL] [Abstract][Full Text] [Related]
10. Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. Zargar-Shoshtari K; Kongnyuy M; Sharma P; Fishman MN; Gilbert SM; Poch MA; Pow-Sang JM; Spiess PE; Zhang J; Sexton WJ World J Urol; 2016 Nov; 34(11):1567-1573. PubMed ID: 27072536 [TBL] [Abstract][Full Text] [Related]
11. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Fahmy O; Khairul-Asri MG; Schubert T; Renninger M; Malek R; Kübler H; Stenzl A; Gakis G Urol Oncol; 2018 Feb; 36(2):43-53. PubMed ID: 29102254 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. Hanna N; Trinh QD; Seisen T; Vetterlein MW; Sammon J; Preston MA; Lipsitz SR; Bellmunt J; Menon M; Choueiri TK; Abdollah F Eur Urol Oncol; 2018 May; 1(1):83-90. PubMed ID: 31100232 [TBL] [Abstract][Full Text] [Related]
13. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Petrelli F; Coinu A; Cabiddu M; Ghilardi M; Vavassori I; Barni S Eur Urol; 2014 Feb; 65(2):350-7. PubMed ID: 23849998 [TBL] [Abstract][Full Text] [Related]
14. Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder Cancer. Chappidi MR; Kates M; Brant A; Baras AS; Netto GJ; Pierorazio PM; Hahn NM; Bivalacqua TJ Urology; 2017 Apr; 102():148-158. PubMed ID: 28104421 [TBL] [Abstract][Full Text] [Related]
15. Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy. Milenkovic U; Akand M; Moris L; Demaegd L; Muilwijk T; Bekhuis Y; Laenen A; Van Cleynenbreugel B; Everaerts W; Van Poppel H; Dumez H; Albersen M; Joniau S World J Urol; 2019 Sep; 37(9):1857-1866. PubMed ID: 30519746 [TBL] [Abstract][Full Text] [Related]
16. Cystectomy vs. bladder preservation after neoadjuvant chemotherapy in muscle-invasive bladder cancer: A tertiary medical center experience. Halabi IE; Husseini ZE; Haibe Y; Charafeddine M; Mukherji D; Temraz S; Bulbul M; Khauli R; Nasr R; Wazzan W; Hajj AE; Geara F; Shamseddine A Cancer Treat Res Commun; 2020; 25():100222. PubMed ID: 33080450 [TBL] [Abstract][Full Text] [Related]
17. Comparing Pathologic and Survival Outcomes Between Primary and Secondary Muscle Invasive Bladder Cancer When Treated by Radical Cystectomy With or Without Neoadjuvant Chemotherapy. Benidir T; Lone Z; Zhang A; Nowacki AS; Munoz-Lopez C; Hegde P; Fung K; Fajnzylber J; Abouassaly R; Berglund R; Klein EA; Eltemamy M; Kaouk J; Weight CJ; Almassi N; Pascal-Haber G; Lee BH Urology; 2022 Oct; 168():137-142. PubMed ID: 35772481 [TBL] [Abstract][Full Text] [Related]
18. Persistent muscle-invasive bladder cancer after neoadjuvant chemotherapy: an analysis of Surveillance, Epidemiology and End Results-Medicare data. Lane G; Risk M; Fan Y; Krishna S; Konety B BJU Int; 2019 May; 123(5):818-825. PubMed ID: 30126053 [TBL] [Abstract][Full Text] [Related]
19. Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case-control matching study. van Ginkel N; Hermans TJN; Meijer D; Boormans JL; Voortman J; Mertens L; van Beek SC; Vis AN; Int Urol Nephrol; 2022 Dec; 54(12):3145-3152. PubMed ID: 35997906 [TBL] [Abstract][Full Text] [Related]
20. Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis. Zhou YX; Hu QC; Zhu YJ; Mu XL; Liu JY; Chen Y Eur J Med Res; 2023 Oct; 28(1):422. PubMed ID: 37822001 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]